RAMM Pharma Résultats passés
Passé contrôle des critères 0/6
RAMM Pharma's earnings have been declining at an average annual rate of -12.9%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been declining at an average rate of 4.5% per year.
Informations clés
-12.9%
Taux de croissance des bénéfices
1.2%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 23.1% |
| Taux de croissance des recettes | -4.5% |
| Rendement des fonds propres | -34.7% |
| Marge nette | -198.5% |
| Dernière mise à jour des bénéfices | 31 Jul 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment RAMM Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Jul 24 | 4 | -9 | 7 | 0 |
| 30 Apr 24 | 5 | -9 | 7 | 0 |
| 31 Jan 24 | 5 | -8 | 7 | 0 |
| 31 Oct 23 | 5 | -8 | 7 | 0 |
| 31 Jul 23 | 5 | -20 | 9 | 0 |
| 30 Apr 23 | 5 | -20 | 8 | 0 |
| 31 Jan 23 | 4 | -21 | 8 | 0 |
| 31 Oct 22 | 4 | -21 | 8 | 0 |
| 31 Jul 22 | 4 | -7 | 7 | 0 |
| 30 Apr 22 | 4 | -9 | 8 | 0 |
| 31 Jan 22 | 4 | -8 | 7 | 0 |
| 31 Oct 21 | 4 | -7 | 7 | 0 |
| 31 Jul 21 | 4 | -7 | 7 | 0 |
| 30 Apr 21 | 4 | -6 | 7 | 0 |
| 31 Jan 21 | 5 | -7 | 8 | 0 |
| 31 Oct 20 | 5 | -7 | 9 | 0 |
| 31 Jul 20 | 6 | -10 | 7 | 0 |
| 30 Apr 20 | 6 | -9 | 6 | 0 |
| 31 Jan 20 | 5 | -9 | 4 | 0 |
| 31 Oct 19 | 6 | -7 | 3 | 0 |
| 31 Oct 18 | 8 | -1 | 2 | 0 |
Des revenus de qualité: RAMM is currently unprofitable.
Augmentation de la marge bénéficiaire: RAMM is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RAMM is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accélération de la croissance: Unable to compare RAMM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: RAMM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement des fonds propres
ROE élevé: RAMM has a negative Return on Equity (-34.75%), as it is currently unprofitable.